Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

Half of pain patients discontinued use of opioids, and another 30% were able to transition off all pain medication, according to OPERA study authors
Cone snail venom offers new therapeutic - and opioid alternative - possibilities for neutralizing chronic pain.
Consensus recommendations for the best way to employ urine drug monitoring when prescribing opioids for patients with chronic pain in primary care.
Two studies published in the New England Journal of Medicine report favorable results when targeting calcitonin gene-related peptide with mAb treatments for migraine pain.
Researchers presented a methodology for stimulating new tissue formation based on cyclical hydrostatic pressure, perhaps leading to cartilage regeneration as a means to restore joint health.
IV infused golimumab may improve function and disease management in patients suffering from inflammatory and joint pain.
In 2015, PPM published “Methadone for Pain Management,”1 which cited that one-third of opioid-implicated deaths were caused by methadone.
Patients who take opioids and drink coffee less pain-related symptoms and depressiion, and higher physical function than patients taking opioids who avoid caffeine.
The first, wearable, noninvasive neurostimulation device, the Bridge, reduced symptoms of opioid withdrawal to achieve 89% success in transitioning to long-term care.
New pain management formulations may impact opioid prescribing and usage: Scripps looks into the G protein and beta-arestin pathways, including fentanyls's role, Daiichi Sankyo releases MorphaBond ER, and FDA moves forward two buprenorphine products to treat opioid use disorder.
With John J. Han, MD, and Tiziano Marovino, DT, MPH
Investigational biologic from Novartis (Cosentyx) may reduce joint pain and tenderness in patients with psoriatic arthritis.
A second Phase 3 trial of tenapanor (T3MPO-2)1 shows promise for relieving symptoms in patients with constipation-predominant irritable bowel syndrome (IBS-C).
A new sufentanil sublingual tablet may provide clinicians and patients with simpler means of dosing and drug delivery.